Slayback's Generic Baclofen Receives Approval in the U.S.
Slayback Pharma's Generic Brimonidine Tartrate Receives Tentative Approval in U.S.
Slayback Pharma's Generic Methylprednisolone Acetate Receives Approval in U.S.
Slayback's Generic Arformoterol Tartrate Receives Approval in the U.S.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (“Slayback”), to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Pfizer Inc. filed lawsuits alleging two generic versions of Xeljanz proposed by Teva Pharmaceuticals USA Inc. and Slayback Pharma LLC each infringe a different patent for the blockbuster arthritis drug.